Literature DB >> 24632508

Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk.

Anne Langsted1, Pia R Kamstrup1, Børge G Nordestgaard2.   

Abstract

OBJECTIVE: There are no recommendations in guidelines on measuring lipoprotein(a) in the fasting or nonfasting state, or on the influence of inflammation. We tested the hypotheses that lipoprotein(a) levels change only minimally in response to normal food intake, and to inflammation. Also, we tested whether normal food intake or inflammation influenced lipoprotein(a)'s ability to predict ischemic heart disease.
METHODS: We studied 34 829 individuals from the Danish general population using the Copenhagen General Population Study and the Copenhagen City Heart Study.
RESULTS: Lipoprotein(a) levels did not change in response to normal food intake: median fasting levels were 17.3 mg/dL, while median levels at 3-4 h since last meal were 19.4 mg/dL(p = 0.38). Lipoprotein(a) levels increased minimally with increasing levels of C-reactive protein(CRP): median lipoprotein(a) levels at CRP <1 mg/L were 18.0 mg/dL, while median levels at CRP >10 mg/L were 21.1 mg/dL(p < 0.001). Furthermore, highest versus lowest tertile of lipoprotein(a) at <3 h and ≥3 h since last meal was associated with a 1.4(95%CI:1.2-1.6) and 1.4(1.2-1.6) fold increased risk of ischemic heart disease(p = 0.82), and a 1.8(1.5-2.2) and 1.4(1.1-1.7) fold increased risk of myocardial infarction(p = 0.05). The corresponding odds ratios at CRP levels of <2 mg/L and ≥2 mg/L were 1.3(1.2-1.5) and 1.4(1.2-1.6)(p = 0.80) for ischemic heart disease, and 1.5(1.2-1.8) and 1.7(1.4-2.0)(p = 0.38) for myocardial infarction.
CONCLUSIONS: Lipoprotein(a) levels did not change in response to normal food intake, but were minimally increased at increased levels of CRP. The ability of elevated lipoprotein(a) levels to predict ischemic heart disease and myocardial infarction in the general population was not affected by normal food intake or inflammation.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Inflammation; Ischemic heart disease; Lipoprotein(a); Myocardial infarction; Nonfasting

Mesh:

Substances:

Year:  2014        PMID: 24632508     DOI: 10.1016/j.atherosclerosis.2014.01.049

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  18 in total

Review 1.  Lipoprotein(a): A Lipoprotein Whose Time Has Come.

Authors:  Erik Kelly; Linda Hemphill
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-07

2.  Lipoprotein(a) screening in young and middle-aged patients presenting with acute coronary syndrome.

Authors:  Ayman Jubran; Anna Zetser; Barak Zafrir
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

3.  Comprehensive Investigation of Circulating Biomarkers and Their Causal Role in Atherosclerosis-Related Risk Factors and Clinical Events.

Authors:  Daniela Zanetti; Stefan Gustafsson; Themistocles L Assimes; Erik Ingelsson
Journal:  Circ Genom Precis Med       Date:  2020-10-30

4.  Coronary Artery Disease Severity and Cardiovascular Biomarkers in Patients with Peripheral Artery Disease.

Authors:  Hiroyuki Hikita; Takatoshi Shigeta; Shigeki Kimura; Atsushi Takahashi; Mitsuaki Isobe
Journal:  Int J Angiol       Date:  2015-06-26

Review 5.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

Review 6.  Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases.

Authors:  Florian Kronenberg
Journal:  Cardiovasc Drugs Ther       Date:  2016-02       Impact factor: 3.727

7.  Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease.

Authors:  Frank van Buuren; Dieter Horstkotte; Cornelius Knabbe; Dennis Hinse; Klaus Peter Mellwig
Journal:  Clin Res Cardiol Suppl       Date:  2017-03

8.  Lipoprotein(a).

Authors:  Florian Kronenberg
Journal:  Handb Exp Pharmacol       Date:  2022

9.  Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a).

Authors:  Konstantin A Krychtiuk; Stefan P Kastl; Sebastian L Hofbauer; Anna Wonnerth; Georg Goliasch; Maria Ozsvar-Kozma; Katharina M Katsaros; Gerald Maurer; Kurt Huber; Elisabeth Dostal; Christoph J Binder; Stefan Pfaffenberger; Stanislav Oravec; Johann Wojta; Walter S Speidl
Journal:  J Clin Lipidol       Date:  2015-04-25       Impact factor: 4.766

10.  Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.

Authors:  Børge G Nordestgaard; Anne Langsted; Samia Mora; Genovefa Kolovou; Hannsjörg Baum; Eric Bruckert; Gerald F Watts; Grazyna Sypniewska; Olov Wiklund; Jan Borén; M John Chapman; Christa Cobbaert; Olivier S Descamps; Arnold von Eckardstein; Pia R Kamstrup; Kari Pulkki; Florian Kronenberg; Alan T Remaley; Nader Rifai; Emilio Ros; Michel Langlois
Journal:  Eur Heart J       Date:  2016-04-26       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.